For localized information and support, would you like to switch to your country-specific website for {0}?
Next-generation sequencing assays for precision oncology
Solution
Deliver critical oncology insights with our portfolio of NGS assays
Precision oncology aims to personalize cancer treatment by identifying targetable alterations in a tumor. Next-generation sequencing (NGS) enables the accurate interrogation of large numbers of genes in parallel, thereby providing the comprehensive information necessary to inform decisions regarding targeted therapies. As the need for precision oncology expands, NGS assays will become an indispensable tool in clinical oncology research, delivering more insights more quickly.1
Our broad portfolio of innovative NGS assays for oncology research is designed to help you and your laboratory achieve your objectives. AVENIO NGS Oncology Assay kits offer in-house tumor profiling, comprehensive genomic profiling (CGP), as well as surveillance and monitoring.2
Value
Versatile NGS assay portfolio with integrated end-to-end workflows
AVENIO NGS Oncology Assay kits provide researchers with a versatile solution for tumor tissue and ctDNA analysis with an integrated end-to-end research workflow.
Whether you require the detection of ultra-low quantities of ctDNA, or work with challenging formalin-fixed paraffin-embedded (FFPE) tissue samples, AVENIO NGS Oncology Assays offer accurate and reliable in-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance & monitoring.2
AVENIO NGS Oncology Assay kits include all of the reagents for DNA extraction, sample input QC (tissue only), library preparation, and target enrichment; as well as robust bioinformatics and secondary analysis (variant analysis)—all from a single, trusted source. The highly efficient workflow has been optimized to minimize hands-on time and deliver high-quality results in just five days—making it easy for you to obtain reliable genomic insights in your lab.
Vision
Shaping the future of oncology: NGS assays that inspire clinical breakthroughs
Treating cancer demands a personalized approach, relying on high-quality assays, validated bioinformatics pipelines and workflows, and the relentless pursuit to provide patients with better healthcare outcomes.
Roche has developed a broad portfolio of NGS assay solutions based on extensive expertise in oncology and diagnostics, which informs high-quality research.
Featured products
Leverage the depth and breadth of next-generation sequencing for precision oncology.
RUO
For Research Use Only. Not for use in diagnostic procedures.
AVENIO Tumor Tissue CGP Kit V2
The AVENIO Tumor Tissue CGP Kit V2 is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors.
RUO
For Research Use Only. Not for use in diagnostic procedures.
AVENIO Tumor Tissue CGP Automated Kit
The AVENIO Tumor Tissue CGP Automated Kit is a next-generation sequencing (NGS) assay that delivers comprehensive genomic profiling (CGP) of solid tumors.
Benefits of NGS assays from Roche
Versatile portfolio
Versatile portfolio of NGS assays to suit your research needs
AVENIO NGS Oncology Assay kits provide researchers with a versatile solution for tumor tissue and ctDNA analysis.
- Accurate and reliable detection and analysis of ultra-low quantities of ctDNA, as well as robust analysis of challenging formalin-fixed paraffin-embedded (FFPE) tissue samples
- In-house tumor profiling, comprehensive genomic profiling (CGP), and surveillance and monitoring2
- Two Comprehensive Genomic Profiling (CGP) Kits with a 335-gene panel aligned with the FoundationOne® CDx panel design. These kits enable detection of four classes of genomic variants (single nucleotide variants, insertions/deletions, copy number variants, and rearrangements/fusions), and complex genomic signatures such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), genomic Loss of Heterozygosity (gLOH), as well as the newly added Homologous Recombination Deficiency signature (HRDsig)3,4
End-to-end workflow
Fully integrated, optimized end-to-end workflow
AVENIO NGS Oncology Assays are designed to make it easy for you to obtain reliable genomic tumor insights in your lab.
- Matched tissue and ctDNA panels (same genes, gene regions, and hybrid-capture workflow) for true concordance*
- All four mutation classes (SNVs, indels, fusions, and CNVs) in a single DNA workflow4
- Streamlined, end-to-end research workflow optimized to minimize hands-on time and deliver high-quality results (DNA extraction to analysis and reporting) in just five days
- Integrated solutions that include reagents, intuitive analysis, and variant reporting—to facilitate in-house adoption of high-performance NGS assays for oncology research
Robust performance
Robust performance from your trusted partners in oncology research
AVENIO NGS assays were rigorously optimized using thousands of samples.
- As a result, AVENIO assays deliver the exceptional performance you expect from Roche and Foundation Medicine, diagnostic leaders and your trusted partners in oncology research
- Leveraging the FoundationOne® Analysis Platform for bioinformatics and secondary analysis, and the AVENIO workflows, the AVENIO Tumor Tissue CGP kits are part of Roche’s broad portfolio that offers flexible CGP solutions and support services to meet your research needs
- AVENIO NGS Oncology Assays produce extremely high levels of sensitivity and specificity for the detection of SNVs, indels, fusions, and CNVs2
AVENIO NGS Oncology Assays brochure
An overview of AVENIO assays and workflows, including a kit selection guide for tumor profiling, CGP, or surveillance and monitoring with easy-to-understand research use case examples.
*CGP is available for tissue only.
AVENIO products are for Research Use Only. Not for use in diagnostic procedures.
References
- Morash M, et al. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018 Sep;8(3):30.
- F. Hoffmann-La Roche. Data on file.
- Choi J et al. Evolution of a Comprehensive Genomic Profiling (CGP) Kit to Simplify Workflows and Detect Homologous Recombination Deficiency. Poster presented at: Association of Molecular Pathology Europe; 2024 June 24-26; Madrid, Spain. Poster# ST-19. Available from: https://medically.roche.com/global/en/oncology/amp-eu-2024/medical-material/AMP-EU-2024-poster-zhang-evolution-of-a-comprehensive-pdf.html.
- F. Hoffmann- La Roche. AVENIO Tumor Tissue CGP Kit V2 Instructions for Use. (v2.0). June 2025.